Journal Home
Search for

Volume 77, Issue 5, Pages 1309-1314 (1 August 2010)


View previous. 5 of 53 View next.

Intraoperative Radiotherapy as a Boost During Breast-Conserving Surgery Using Low-Kilovoltage X-Rays: The First 5 Years of Experience With a Novel Approach

Frederik Wenz, M.D.Corresponding Author Informationemail address, Grit Welzel, M.Sc., Elena Blank, M.S., Brigitte Hermann, M.D., Volker Steil, M.Sc., Marc Sütterlin, M.D., Uta Kraus-Tiefenbacher, M.D.

Received 30 April 2009; received in revised form 19 June 2009; accepted 23 June 2009. published online 25 January 2010.

Purpose

Intraoperative radiotherapy (IORT) during breast-conserving surgery (BCS) has been recently introduced using different devices. We report the first 5 years of a single-center experience after introduction of a novel approach to deliver IORT as a tumor bed boost during BCS for breast cancer.

Methods and Materials

A total of 155 breast cancers in 154 women (median age, 63 years; range, 30–83 years; T1/T2 = 100/55; N0/N+ = 108/47) were treated between February 2002 and December 2007 at the University Medical Center Mannheim, in whom IORT as tumor bed boost was applied using 50-kV X-rays (20 Gy) followed by 46–50 Gy whole-breast external-beam radiotherapy (EBRT). Chemotherapy, if indicated, was given before EBRT. The median interval between BCS plus IORT and EBRT was 40 days. Median follow-up was 34 months (maximum 80 months, 1 patient lost to follow-up). Overall survival and local relapse-free survival were calculated at 5 years using the Kaplan-Meier method. Seventy-nine patients were evaluated at 3-year follow-up for late toxicity according to the Late Effects in Normal Tissues–Subjective, Objective, Management, and Analytic system.

Results

Ten patients died, 2 had in-breast relapse, and 8 developed distant metastases (5-year overall survival = 87.0%; 5-year local relapse-free survival = 98.5%). Grade 3 fibroses of the tumor bed were detected in 5% of the patients after 3 years. Skin toxicity was mild (telangiectases and hyperpigmentations in approximately 6% each).

Conclusions

Intraoperative radiotherapy as a tumor bed boost during BCS for breast cancer using low-kilovoltage X-rays followed by EBRT yields low recurrence and toxicity rates.

 Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany

 Department of Obstetrics and Gynecology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany

Corresponding Author InformationReprint requests to: Frederik Wenz, M.D., Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68167 Mannheim, Germany. Tel: (+49) 621-383-4960; Fax: (+49) 621-383-733496

 Supported by grants from the Bundesministeriums für Bildung und Forschung and the Dietmar Hopp Stiftung.

 Conflict of interest: Radiobiologic research in the laboratory of F. Wenz is supported by Carl Zeiss Oberkochen.

PII: S0360-3016(09)02798-9

doi:10.1016/j.ijrobp.2009.06.085


View previous. 5 of 53 View next.